404589-70-4

Basic information

• Product Name: Ethanone, 2-chloro-1-[1-(4-chlorophenyl)cyclobutyl]-
• CAS NO: 404589-70-4
• Molecular Formula: C12H12Cl2O
• Molecular Weight: 243.133
• Mol File: 404589-70-4.mol
• Article Data: 5

Chemical Properties

• CAS DataBase Reference: Ethanone, 2-chloro-1-[1-(4-chlorophenyl)cyclobutyl]-(CAS DataBase Reference)
• NIST Chemistry Reference: Ethanone, 2-chloro-1-[1-(4-chlorophenyl)cyclobutyl]-(404589-70-4)
• EPA Substance Registry System: Ethanone, 2-chloro-1-[1-(4-chlorophenyl)cyclobutyl]-(404589-70-4)

Safety Data

• Hazardous Substances Data: 404589-70-4(Hazardous Substances Data)

Upstream product

• 186581-53-3 diazomethane 
• 89421-95-4 l-(4-chloro-phenyl)-cyclobutanecarbonyl chloride 

Downstream Products

• 1067187-73-8 2-(1-(4-chlorophenyl)cyclobutyl)-2-oxoethyl acetate 
• 1009376-49-1 C₂₆H₂₉ClF₃NO₂ 
• 473705-85-0 N'-{4-[1-(4-chlorophenyl)cyclobutyl]thiazol-2-yl}-N,N-diethylpropane-1,3-diamine 
• 473705-93-0 1-{4-[1-(4-chlorophenyl)cyclobutyl]thiazol-2-yl}-4-methylpiperazine 

Relevant articles and documents

MULTIMEDIATOR TRANSPORTER INHIBITORS FOR USE IN TREATMENT OF CENTRAL NERVOUS SYSTEM DISORDERS

The invention provides a class of inhibitors, packaged pharmaceuticals comprising such inhibitors, and uses of the inhibitors in treating, or the manufacturing medicaments for treating central nervous system disorders, including depression, anxiety, sleep

Methods and Compositions for Selectin Inhibition

The present teachings relate to novel compounds of formula I: wherein the constituent variables are as defined herein. Compounds of the present teachings can act as antagonists of the mammalian adhesion proteins known as selecting. Methods for treating or preventing selectin-mediated disorders are provided, which include administration of these compounds in a therapeutically effective amount.

Thiazole and other heterocyclic ligands for mammalian dopamine, muscarinic and serotonin receptors and transporters, and methods of use thereof

One aspect of the present invention relates to novel heterocyclic compounds. A second aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for various mammalian cellular receptors, including G-protein coupled receptors. A third aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors or transporters. Another aspect of the present invention relates to the use of the novel heterocyclic compounds as ligands for mammalian dopamine, muscarinic or serotonin receptors. The compounds of the present invention will also find use in the treatment of numerous ailments, conditions and diseases which afflict mammals, including but not limited to addiction, anxiety, depression, sexual dysfunction, hypertension, migraine, Alzheimer's disease, obesity, emesis, psychosis, analgesia, schizophrenia, Parkinson's disease, restless leg syndrome, sleeping disorders, attention deficit hyperactivity disorder, irritable bowel syndrome, premature ejaculation, menstrual dysphoria syndrome, urinary incontinence, inflammatory pain, neuropathic pain, Lesche-Nyhane disease, Wilson's disease, Tourette's syndrome, psychiatric disorders, stroke, senile dementia, peptic ulcers, pulmonary obstruction disorders, and asthma.